Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Claritin Patent Ruling Unlikely To Affect Clarinex Exclusivity

Executive Summary

The outcome of Schering-Plough's Claritin patent litigation is unlikely to have a significant effect on the exclusivity for the successor drug Clarinex

You may also be interested in...



Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims

Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case

Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims

Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case

Claritin Patent Case May Define Value Of Metabolite Patents

Innovators will still have a viable method for protecting metabolites if the Claritin patent ruling is upheld, a federal appellate court judge said April 8

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel